高级检索
当前位置: 首页 > 详情页

The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biomed Engn, Wuhan 430074, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurosurg, Wuhan 430022, Peoples R China [3]China Japan Friendship Hosp, Dept Neurosurg, Beijing 100029, Peoples R China
出处:
ISSN:

关键词: anti-angiogenic IP-10 immunotherapy cytolytic T lymphocyte

摘要:
The purpose of the present Study Was to evaluate the anti-vasculature effects and the anti-tumor effects of attenuated Salmonella typhimurium vaccine strain encoding murine Vascular endothelial growth factor (VEGF) receptor-2 (flk1) in combination with plasmid DNA vector encoding the murine interferon-induced protein of 10 kDa (IP-10 or CXCL10) gene. Mouse models of malignant melanoma (1316410) were treated with Combining Orally given attenuated S. typhimurium vaccine Strain encoding flk1 with direct intratumoral injection of a non-viral plasmid DNA vector encoding the murine IP-10 gene. The volumes of tumors and survival of mice hearing 1316410 tumors were observed. Cytolytic T lymphocyte (CTL) response was measured by cytotoxic assay, vessel density and tumor-cell proliferation were observed by immunostaining, and tumor apoptosis was determined by TUNEL staining. The results revealed the combination therapy groups showed more significantly inhibited tumor growth, apoptosis of tumor cells, and reduced neovascularization, cell proliferation, and developed a strong CTL response in these mice. In summary, the therapy of attenuated S. typhimurium vaccine strain encoding flk1 combined with the IP-10 gene has significant synergistic effect against tumors. (C) 2008 Elsevier Ltd. All rights reserved.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2007]版:
大类 | 3 区 医学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 医学:研究与实验
JCR分区:
出版当年[2006]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 VETERINARY SCIENCES Q2 IMMUNOLOGY
最新[2023]版:
Q2 IMMUNOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2006版] 出版当年五年平均[2002-2006] 出版前一年[2005版] 出版后一年[2007版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Dept Biomed Engn, Wuhan 430074, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)